Ownership Action to Note: Cooper Companies Inc (NYSE:COO) Institutional Investor Sentiment Analysis

November 29, 2016 - By Richard Conner   ·   0 Comments

Ownership Action to Note: Cooper Companies Inc (NYSE:COO) Institutional Investor Sentiment Analysis

Sentiment for Cooper Companies Inc (NYSE:COO)

Cooper Companies Inc (NYSE:COO) institutional sentiment decreased to 1.21 in 2016 Q2. Its down -0.06, from 1.27 in 2016Q1. The ratio worsened, as 172 active investment managers started new or increased positions, while 135 sold and reduced their equity positions in Cooper Companies Inc. The active investment managers in our partner’s database now have: 46.70 million shares, down from 48.33 million shares in 2016Q1. Also, the number of active investment managers holding Cooper Companies Inc in their top 10 positions was flat from 5 to 5 for the same number . Sold All: 26 Reduced: 109 Increased: 130 New Position: 42.

The Cooper Companies, Inc. is a medical device company. The company has a market cap of $8.17 billion. The Firm operates through two business units: CooperVision, Inc. (CooperVision) and CooperSurgical, Inc. (CooperSurgical). It has a 33.27 P/E ratio. CooperVision develops, makes and markets a range of soft contact lenses for the vision correction market.

About 78,148 shares traded hands. Cooper Companies Inc (NYSE:COO) has risen 5.81% since April 26, 2016 and is uptrending. It has outperformed by 0.55% the S&P500.

Analysts await Cooper Companies Inc (NYSE:COO) to report earnings on December, 8 after the close. They expect $2.24 EPS, up 12.00% or $0.24 from last year’s $2 per share. COO’s profit will be $107.71 million for 18.96 P/E if the $2.24 EPS becomes a reality. After $2.30 actual EPS reported by Cooper Companies Inc for the previous quarter, Wall Street now forecasts -2.61% negative EPS growth.

According to Zacks Investment Research, “The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperVision markets a range of contact lenses to correct visual defects, specializing in toric lenses that correct astigmatism. The company also markets conventional toric and spherical lenses and lenses for patients with more complex vision disorders. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women’s healthcare market.”

Nebula Capital Management Lp holds 7.14% of its portfolio in Cooper Companies Inc for 5,257 shares. Bellecapital International Ltd. owns 25,343 shares or 4.76% of their US portfolio. Moreover, Torray Llc has 2.57% invested in the company for 197,644 shares. The Delaware-based Kalmar Investments Inc De has invested 1.79% in the stock. Martin Currie Ltd, a United Kingdom-based fund reported 78,500 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 1 insider buy, and 11 insider sales for $17.60 million net activity.

Cooper Companies Inc (NYSE:COO) Ratings Coverage

Ratings analysis reveals 83% of Cooper’s analysts are positive. Out of 12 Wall Street analysts rating Cooper, 10 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $136 while the high is $215. The stock’s average target of $174.88 is 2.93% above today’s ($169.91) share price. COO was included in 25 notes of analysts from August 26, 2015. The stock of Cooper Companies Inc (NYSE:COO) earned “Neutral” rating by JP Morgan on Friday, December 4. Jefferies maintained it with “Buy” rating and $210 target price in Wednesday, August 24 report. The stock of Cooper Companies Inc (NYSE:COO) earned “Hold” rating by Zacks on Monday, August 31. As per Wednesday, August 26, the company rating was upgraded by KeyBanc Capital Markets. The firm has “Outperform” rating given on Friday, September 4 by BMO Capital Markets. The rating was maintained by BMO Capital Markets with “Outperform” on Friday, September 2. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, November 17. The company was initiated on Wednesday, July 13 by JP Morgan. The stock of Cooper Companies Inc (NYSE:COO) has “Buy” rating given on Friday, September 4 by Piper Jaffray. The stock of Cooper Companies Inc (NYSE:COO) earned “Buy” rating by Cleveland on Monday, May 16.

COO Company Profile

The Cooper Companies, Inc. (Cooper), incorporated on March 4, 1980, is a global medical device company. The Firm operates through two business units, CooperVision, Inc. (CVI) and CooperSurgical, Inc. (CSI). CooperVision is a global maker providing products for contact lens wearers. CooperSurgical focuses on supplying women’s health clinicians with products and treatment options to improve the delivery of healthcare to women. CooperSurgical products fall into three main divisions based on the point of healthcare delivery: Hospital, Office and Fertility Clinic. CooperVision develops, makes and markets a range of monthly, two-week and single-use contact lenses, featuring advanced materials and optics. CooperVision’s products are designed to solve vision challenges such as astigmatism, presbyopia and ocular dryness with a collection of spherical, toric and multifocal contact lenses. The CooperVision Company’s brands include Biofinity, Avaira, Proclear and MyDay and the CooperSurgical Company’s brands include Advincula Arch, SeeClear, Lone star and Mobius.

Another recent and important Cooper Companies Inc (NYSE:COO) news was published by Globenewswire.com which published an article titled: “The Cooper Companies Acquires Assets of Recombine” on May 25, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>